Thalassemia Major Clinical Trial
Official title:
The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study
This is a prospective, single-arm, open-label study. Twenty adult patients with transfusion-dependent β -thalassemia will be enrolled to receive Luspatercept with optimal supportive care, including blood transfusion and iron removal, based on the clinician's judgment and practice. The main objective of this study was to evaluate the efficacy and safety of Luspatercept in the treatment of adult patients with transfusion-dependent β -thalassaemia in Chinese clinical practice, and to provide evidence reference for subsequent clinical use.
Twenty adult patients with transfusion-dependent β -thalassemia will be enrolled to receive Luspatercept with optimal supportive care, being injected subcutaneously every 3 weeks ,by the dose of 1-1.25 mg/kg. The main objective of this study was to evaluate the efficacy and safety of Luspatercept in the treatment of adult patients with transfusion-dependent β -thalassaemia in Chinese clinical practice, and to provide evidence reference for subsequent clinical use. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02559648 -
Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis
|
Phase 2 | |
| Recruiting |
NCT02126046 -
Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major
|
N/A | |
| Completed |
NCT01125254 -
Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
|
Phase 2/Phase 3 | |
| Terminated |
NCT00034528 -
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
|
Phase 2 | |
| Completed |
NCT00733811 -
Efficacy Study of the Use of Sequential DFP-DFO Versus DFP
|
Phase 4 | |
| Enrolling by invitation |
NCT02986698 -
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)
|
Phase 1 | |
| Not yet recruiting |
NCT06026839 -
Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors
|
||
| Terminated |
NCT00007072 -
Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major
|
Phase 2 | |
| Completed |
NCT04292314 -
Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia
|
Phase 2/Phase 3 | |
| Completed |
NCT02049450 -
Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
|
Phase 2 | |
| Active, not recruiting |
NCT04523376 -
Pilot Study PBSCT With TCRab Depletion For Hemoglobinopathies
|
N/A | |
| Completed |
NCT03992001 -
Impact of the Preparation Method of Red Cell Concentrates on Transfusion Indices in Thalassemic Patients
|
Phase 4 | |
| Not yet recruiting |
NCT05777733 -
NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major
|
Phase 1 | |
| Completed |
NCT01241357 -
High-Tc Susceptometer to Monitor Transfusional Iron Overload
|
Phase 2 | |
| Completed |
NCT00749515 -
Pilot Study for Patients With Poor Response to Deferasirox
|
Phase 4 | |
| Completed |
NCT04260516 -
The Effect of N-acetylcysteine on Oxidative Stress Status and Iron Overload in Thalassemia Major
|
Phase 1 | |
| Recruiting |
NCT02307786 -
Long Term Outcomes in β Thalassemia Major
|
N/A | |
| Not yet recruiting |
NCT01323608 -
The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study
|
Phase 4 | |
| Completed |
NCT00005893 -
Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders
|
N/A | |
| Recruiting |
NCT06137079 -
"Iron Overload and Endocrinological Diseases"
|